Skip to main content

ASTROTECH Corp

For the period ended Mar 31, 2026. Filed May 13, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 13, 2026

ASTC$4.27-1.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

ITEM 1.** Condensed Consolidated Financial Statements

Condensed Consolidated Balance Sheets

(In thousands, except share and per share data)

March 31,June 30,
20262025
(Unaudited)(Note)
Assets
Current assets
Cash and cash equivalents$2,679$3,100
Short-term investments3,90315,108
Accounts receivable504485
Inventory, net:
Raw materials3,0192,194
Work-in-process531425
Finished goods310310
Prepaid expenses and other current assets383353
Total current assets11,32921,975
Property and equipment, net2,5732,395
Intangible asset, net5048
Operating lease right-of-use assets, net1,9062,225
Other assets, net315346
Total assets$16,173$26,989
Liabilities and stockholders’ equity
Current liabilities
Accounts payable$234$1,066
Payroll related accruals461529
Accrued expenses and other liabilities865451
Lease liabilities, current275405
Total current liabilities1,8352,451
Accrued expenses and other liabilities, net of current portion79164
Lease liabilities, net of current portion2,1042,274
Total liabilities4,0184,889
Commitments and contingencies (Note 15)
Stockholders’ equity
Convertible preferred stock, $0.001 par value, 2,500,000 shares authorized; 280,898 shares of Series D issued and outstanding at March 31, 2026, and June 30, 2025——
Common stock, $0.001 par value, 250,000,000 shares authorized at March 31, 2026, and June 30, 2025, respectively; 1,769,269 shares issued at March 31, 2026, and June 30, 2025 respectively; 1,758,953 shares outstanding at March 31, 2026, and June 30, 2025.190,643190,643
Treasury shares, 10,316 at March 31, 2026, and June 30, 2025, respectively(119)(119)
Additional paid-in capital84,05083,310
Accumulated deficit(262,030)(250,870)
Accumulated other comprehensive loss(389)(864)
Total stockholders’ equity12,15522,100
Total liabilities and stockholders’ equity$16,173$26,989

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except per share data)

Three Months Ended · Nine Months Ended
March 31,March 31,
2026202520262025
Revenue$343$534$787$829
Cost of revenue276297525428
Gross profit67237262401
Operating expenses:
Selling, general and administrative2,0852,1155,9415,842
Research and development1,4351,9895,2116,375
Total operating expenses3,5204,10411,15212,217
Loss from operations(3,453)(3,867)(10,890)(11,816)
Other income and expense, net(315)234(271)896
Loss from operations before income taxes(3,768)(3,633)(11,161)(10,920)
Net loss$(3,768)$(3,633)$(11,161)$(10,920)
Weighted average common shares outstanding:
Basic and diluted1,6771,6651,6761,663
Basic and diluted net loss per common share:
Net loss per common share$(2.25)$(2.18)$(6.66)$(6.57)
Other comprehensive loss, net of tax:
Net loss$(3,768)$(3,633)$(11,161)$(10,920)
Available-for-sale securities:
Net unrealized gain (loss)159139476236
Total comprehensive loss$(3,609)$(3,494)$(10,685)$(10,684)

ASTROTECH CORPORATION

Condensed Consolidated Statement of Changes in Stockholders’** Equity**

(In thousands)

Preferred Stock
Series D · Common Stock
Number of Shares OutstandingAmountNumber of Shares OutstandingAmountTreasury Stock AmountAdditional Paid-In CapitalAccumulated DeficitAccumulated Other Comprehensive LossTotal Stockholders’ Equity
Balance at June 30, 2025281$—1,759$190,643$(119)$83,310$(250,870)$(864)$22,100
Net change in available-for-sale marketable securities———————148148
Stock offering costs—————-——-
Stock-based compensation—————304——304
Issuance of restricted stock—————————
Forfeiture of stock options—————————
Exercise of stock options—————————
Share repurchases—————————
Cancellation of restricted stock——-——-——-
Net loss——————(3,465)—(3,465)
Balance at September 30, 2025281$—1,759$190,643$(119)$83,614$(254,335)$(716)$19,087
Net change in available-for-sale marketable securities———————168168
Issuance of stock, net of offering costs————-
Stock-based compensation—————190——190
Cancellation of restricted stock——-——-——-
Exercise of stock options———————
Share repurchases———————
Restricted stock issuance---————
Net loss——————(3,927)—(3,927)
Balance at December 31, 2025281$—1,759$190,643$(119)$83,804$(258,262)$(548)$15,518
Net change in available-for-sale marketable securities———————159159
Stock-based compensation—————246——246
Cancellation of restricted stock—————————
Purchase of treasury stock————-
Net loss——————(3,768)—(3,768)
Balance at March 31, 2026281$—1,759$190,643$(119)$84,050$(262,030)$(389)$12,155
Preferred Stock
Series D · Common Stock
Number of Shares OutstandingAmountNumber of Shares OutstandingAmountTreasury Stock AmountAdditional Paid-In CapitalAccumulated DeficitAccumulated Other Comprehensive LossTotal Stockholders’ Equity
Balance at June 30, 2024281$—1,702$190,643$(119)$82,480$(237,020)$(1,177)$34,807
Net change in available-for-sale marketable securities———————316316
Stock-based compensation—————216——216
Net loss——————(3,278)—(3,278)
Balance at September 30, 2024281$—1,702$190,643$(119)$82,696$(240,298)$(861)$32,061
Net change in available-for-sale marketable securities———————(219)(219)
Stock-based compensation—————261——261
Net loss——————(4,009)—(4,009)
Balance at December 31, 2024281$—1,702$190,643$(119)$82,957$(244,307)$(1,080)$28,094
Net change in available-for-sale marketable securities———————139139
Stock-based compensation—————152——152
Cancellation of restricted stock——(8)——————
Purchase of treasury stock————————-
Net loss——————(3,633)—(3,633)
Balance at March 31, 2025281$—1,694$190,643$(119)$83,109$(247,940)$(941)$24,752

** ASTROTECH CORPORATION AND SUBSIDIARIES**

Condensed Consolidated Statements of Cash Flows

(In thousands)

Nine Months Ended
March 31,
20262025
Cash flows from operating activities:
Net loss$(11,161)$(10,920)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation740629
Depreciation and amortization684718
Amortization of operating lease right-of-use assets210107
Interest on financing leases(3)4
Loss on disposal of asset21097
Changes in assets and liabilities:
Accounts receivable(19)(439)
Contract asset—(7)
Inventory, net(1,112)(278)
Accounts payable(832)243
Other assets and liabilities287(627)
Operating lease liabilities(169)(118)
Net cash used in operating activities(11,165)(10,591)
Cash flows from investing activities:
Purchases of property and equipment(857)(485)
Purchases of intangible assets—(50)
Proceeds from short-term investments11,6813,653
Net cash provided by investing activities10,8243,118
Cash flows from financing activities:
Repayment of financing liability in connection with internal-use software(63)(70)
Repayments on finance lease liabilities(17)(87)
Net cash used in financing activities(80)(157)
Net change in cash and cash equivalents$(421)$(7,630)
Cash and cash equivalents at beginning of period3,10010,442
Cash and cash equivalents at end of period$2,679$2,812
Supplemental disclosures of cash flow information:
Cash paid for interest$3$9
Non-cash financing activities: Transfer from inventory181—
Operating right of use assets interests8721

Notes to Condensed Consolidated Financial Statements (Unaudited)

(1) General Information

Business Overview

The terms “Astrotech”, “the Company”, “we”, “us”, or “our” refer to Astrotech Corporation (Nasdaq: ASTC), a Delaware corporation organized in1984.

Our mission is to expand access to mass spectrometry ("MS") and its use through the deployment of devices designed specifically for the appropriate levels of precision required in high-volume, real-time testing environments such as airports, border checkpoints, cargo hubs, infrastructure security, correctional facilities, military bases, law enforcement centers, and industrial locations. The Astrotech Mass Spectrometer Technology™ (“AMS Technology”) platform achieves our mission through simplifying the user interface, automating the complicated calibration process, ruggedizing the critical components to endure MS field work, and enabling multiple configurations for sample intake options.

We are commercializing the AMS Technology through application specific, wholly owned subsidiaries described below.

●Astrotech Technologies, Inc. (“ATI”) owns and licenses the intellectual property related to the AMS Technology.
●1st Detect Corporation (“1st Detect”) is a manufacturer of explosives trace detectors ("ETDs") and narcotics trace detectors (“NTDs”) developed for use in security and detection at airports, border checkpoints, cargo hubs, infrastructure security, correctional facilities, military bases, and law enforcement centers. 1st Detect holds an exclusive AMS Technology license from ATI for air passenger and cargo security applications as well as narcotics detection.
●AgLAB, Inc. (“AgLAB”) is developing a series of mass spectrometers for use in the hemp and cannabis market with initial focus on optimizing yields in the distillation processes. AgLAB holds an exclusive AMS Technology license from ATI for applications in the agriculture industry which require analyzing complex chemical compounds found in organic plant material and extracts.
●BreathTech Corporation (“BreathTech”) is advancing a breath analysis tool to screen for volatile organic compound (“VOC”) metabolites found in a person’s breath that could indicate a compromised condition including but not limited to a bacterial or viral infection. BreathTech holds an exclusive AMS Technology license from ATI for breath analysis applications.
●Pro-Control, Inc. ("Pro-Control") is focused on applying the AMS Technology in industrial process control applications. The mass spectrometer and process are designed to test, measure and increase reaction intermediates, purity and percent yields in industrial processes. Pro-Control holds an exclusive AMS Technology license from ATI for the distillation of chemicals outside of the agriculture industry.
●EN-SCAN, Inc. (“EN-SCAN”) is developing advanced environmental testing and monitoring solutions, integrating gas chromatography and mass spectrometry technology in rugged, portable designs. EN-SCAN’s products are expected to support industrial, environmental, and regulatory applications, helping organizations meet compliance requirements and environmental safety. EN-SCAN will use proprietary ATi Gas Chromatograph and AMS Technology license from ATI for instant feedback to accurately detect soil, water, and air contamination source location and migration.

Principles of Consolidation and Basis of Presentation

The accompanying condensed consolidated financial statements of Astrotech Corporation and Subsidiaries (collectively the “Company”) have been prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and disclosures required by accounting principles generally accepted in the United States have been condensed or omitted pursuant to such rules and regulations. These condensed financial statements reflect all adjustments that, in the opinion of management, are necessary to present fairly the results of operations of the Company for the period presented. The results of operations for thethree andnine months ended* March 31, 2026*, arenot necessarily indicative of the results that* maybe expected for any future period or the fiscal year ending June 30, 2026* and should be read in conjunction with the Company’s Annual Report on Form10-K for the fiscal year ended* June 30, 2025*, filed with the SEC.

7

Segment Information

The accounting guidance on Segment Reporting establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information of those segments to be presented in financial statements. Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker (the “CODM”), the Chief Executive Officer, in making decisions on how to allocate resources and assess performance. Net sales attributed to customers in the United States and foreign countries for thethree months andnine months ended* March 31, 2026,and March**31,* 2025, were as follows:

Three Months EndedNine Months Ended
Revenue by SegmentMarch 31, 2026March 31, 2025March 31, 2026March 31, 2025
(In thousands)
United States$221487$599$709
Foreign Countries12247188120
Total Revenue$343$534$787$829
Product RevenueThree Months EndedNine Months Ended
(In thousands)March 31, 2026March 31, 2025March 31, 2026March 31, 2025
Product Revenue$147$348220543
Training Revenue——$20—
Grant Revenue(41)6820594
Service Revenue2175629484
Warranty Revenue206248108
Total Revenue$343$534$787$829

Accounting Pronouncements

In* December 2023**,* the FASB issued ASU2023-09*,* “Income Taxes (Topic740):Improvements to Income Tax Disclosures” which is intended to enhance the transparency and decision usefulness of income tax disclosures. The guidance addresses investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. The guidance is effective for annual periods beginning after* December 15, 2024**.* We adopted this standard in fiscal year2025 This pronouncement hasnot impacted the Company’s consolidated financial statements.

Recently Issued Accounting StandardsNot Yet Adopted

In* November 2024,the FASB issued Accounting Standards Update2024*-03 "Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic220-40)" which requires that at each interim and annual reporting period an entity:

1. Disclose the amounts of (a) purchases of inventory, (b) employee compensation, (c) depreciation, (d) intangible asset amortization, and (e) depreciation, depletion, and amortization included in each relevant expense caption. A relevant expense caption is an expense caption presented on the face of the income statement within continuing operations that contains any of the listed expense categories.

2. Include certain amounts that are already required to be disclosed under current generally accepted accounting principles (GAAP) in the same disclosure as the other disaggregation requirements.

3. Disclose a qualitative description of the amounts remaining in relevant expense captions that arenot separately disaggregated quantitatively.

4. Disclose the total amount of selling expenses and, in annual reporting periods, an entity’s definition of selling expenses.

These amendments are effective for annual reporting periods beginning after* December 15, 2026,and interim reporting periods beginning after December 15, 2027:*either (1) prospectively to financial statements issued for reporting periods after the effective date of this Update or (2) retrospectively to any or all prior periods presented in the financial statements. The Company expects to enhance disclosures of expenses based on new requirements.

In* November 2024,the FASB also issued Accounting Standards Update2024*-04 "Debt - Debt with Conversion and Other Options (Subtopic470-20) “Induced Conversions of Convertible Debt Instruments” to clarify the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. Under the amendments, to account for a settlement of a convertible debt instrument as an induced conversion, an inducement offer is required to provide the debt holder with, at a minimum, the consideration (in form and amount) issuable under the conversion privileges provided in the terms of the instrument. An entity should assess whether this criterion is satisfied as of the date the inducement offer is accepted by the holder. If, when applying this criterion, the convertible debt instrument had been exchanged or modified (without being deemed substantially different) within theone-year period leading up to the offer acceptance date, an entity should compare the terms provided in the inducement offer with the terms that existedone year before the offer acceptance date. The amendments in this Update also clarify that the induced conversion guidance applies to a convertible debt instrument that isnot currently convertible as long as it had a substantive conversion feature as of both its issuance date and the date the inducement offer is accepted. The amendments are effective for all entities for annual reporting periods beginning after* December 15, 2025,and interim reporting periods within those annual reporting periods. The Company is examining the impact this pronouncement may*have on the Company’s consolidated financial statements.

Other accounting pronouncements issued butnot yet effective arenot believed by management to be relevant or to have a material impact on the Company’s present or future consolidated financial statements.

8

(2) Liquidity

As of* March 31, 2026,the Company had cash of approximately $2.7 million, short-term investments of approximately $3.9 million , and has positive working capital of approximately $9.5 million. We have incurred recurring losses and negative cash flows from operations since inception and had an accumulated deficit of approximately $262 million at March 31, 2026.Management believes that our cash and cash equivalents, and investments at March 31, 2026,together with operational cash flows, and capital-raising activities will fund our current operating plans and meet our anticipated obligations for at least the next12* months.

Substantial additional capital will be required to support longer-term growth and operational objectives. Future cash flows are subject to a number of variables, including the ability to generate sales under existing and future business opportunities, and significant additional capital expenditures* maybe required to conduct our operations. There can beno* assurance that operations and other capital sources will provide sufficient cash to maintain planned or future levels of capital expenditures.

We regularly monitor potential financings and capital sources, including equity and debt markets, in an effort to meet our planned capital expenditures and liquidity requirements. The availability and terms of future financing will depend on a variety of factors, including general economic and market conditions, our operating performance, and investor interest. Additional funding* may**not* be available on acceptable terms, if at all. If we are unable to obtain adequate financing when needed, we* maybe forced to delay, reduce the scope of, or eliminate certain operations, commercialization efforts, or other aspects of our business. In addition, raising additional funds through equity offerings may*result in dilution to our stockholders, while debt or other financing could involve covenants or obligations that restrict our business operations. Until we can generate sufficient revenue from product sales, if at all, we expect to finance our operations primarily through existing cash reserves and additional capital-raising activities.

9

(3) Investments

The following tables summarize gains and losses related to the Company’s investments as of* March 31, 2026*, and* June 30, 2025*, respectively:

Available-for-Sale InvestmentsAdjustedUnrealizedUnrealizedFair
(In thousands)CostGainLossValue
Mutual Funds - Corporate & Government Debt$4,292$—$(389)$3,903
ETFs - Corporate & Government Debt————
Total$4,292$—$(389)$3,903
Available-for-Sale InvestmentsAdjustedUnrealizedUnrealizedFair
(In thousands)CostGainLossValue
Mutual Funds - Corporate & Government Debt$10,547$—$(668)$9,879
ETFs - Corporate & Government Debt5,425—(196)5,229
Total$15,972$—$(864)$15,108

As of* March 31, 2026*, and* June 30, 2025*, the Company hadno long-term investments. For more information about the fair value of the Company’s financial instruments, see footnote11.

The following table presents the carrying amounts of certain financial instruments as of* March 31, 2026*, and* June 30, 2025*, respectively:

Carrying Value · Carrying Value
Short-Term InvestmentsLong-Term Investments
(In thousands)March 31, 2026June 30, 2025March 31, 2026June 30, 2025
Money Market Funds
Mutual Funds - Corporate & Government Debt$3,903$9,879$—$—
ETFs - Corporate & Government Debt-5,229——
Total$3,903$15,108$—$—

(4) Leases

On* November 22, 2022,Astrotech entered into a sublease agreement for an approximately 3,900 square feet facility to provide the space needed as the Company launches its AgLAB products and continues its R&D efforts at ATI and BreathTech. The sublease commenced on December 1, 2022,and has a lease term of 29 months. This sublease agreement expired on October 31, 2025,and the companyno* longer occupies the space.

On* January 29, 2025,we entered into a new lease agreement for a facility of approximately 17,628 square feet in Austin, Texas (the “Metric Facility”) for a term of 89 months, which such term commences July 1, 2025.*The Metric Facility is intended to support and encompass all Austin-based functions. Our total contractual base rent obligation for the Metric Facility is approximately $3.0 million, less a tenant allowance of $317.3 thousand.

Operating lease assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company’s leases donot provide an implicit rate, the Company uses its incremental borrowing rate in determining the present value of lease payments. Significant judgment is required when determining the Company’s incremental borrowing rate. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The amortization expense for financed lease assets forthree months ended* March**31,* 2026, and2025 totaled $31 thousand in each period.

10

The balance sheet presentation of the Company’s operating and finance leases is as follows:

(In thousands) · Classification on the Condensed Consolidated Balance Sheet · March 31, 2026 · June 30, 2025
Assets:
Operating lease assetsOperating leases, right-of-use assets, net$1,906$2,225
Financing lease assetsProperty and equipment, net$13979
Total lease assets$2,045$2,304
Liabilities:
Current:
Operating lease obligationsLease liabilities, current$251$381
Financing lease obligationsLease liabilities, current2424
Non-current:
Operating lease obligationsLease liabilities, non-current2,0732,225
Financing lease obligationsLease liabilities, non-current3149
Total lease liabilities$2,379$2,679

Future minimum lease payments as of* March 31, 2026*, under non-cancellable leases are as follows (in thousands):

(In thousands)
For the Year Ended June 30,Operating LeasesFinancing LeasesTotal
2026$95$6$101
202736126387
202837426400
2029353—353
2030438—438
Thereafter1,127—1,127
Total lease obligations2,748582,806
Less: imputed interest(424)(3)(427)
Present value of net minimum lease obligations2,324552,379
Less: lease liabilities - current(251)(24)(275)
Lease liabilities - non-current$2,073$31$2,104

Other information as of* March 31, 2026*, is as follows:

Weighted-average remaining lease term (years):
Operating leases6.7
Financing leases2.3
Weighted-average discount rate:
Operating leases4.8%
Financing leases6.1%

Cash payments for operating leases for thethree months ended* March 31, 2026*, and2025 were $95 thousand and $43 thousand, respectively. Cash payments for financing leases for thethree months ended* March 31, 2026*, and2025, were $7 thousand and $9 thousand respectively. Cash payments for operating leases for thenine months ended* March 31, 2026,and2025* were $253 thousand and $128 thousand respectively. Cash payments for financing leases for thenine months ended* March 31, 2026,and2025,* were $17 thousand and $87 thousand respectively.

11

(5) Property and Equipment, net

As of* March 31, 2026*, and* June 30, 2025*, property and equipment, net consisted of the following, respectively:

(In thousands)March 31, 2026June 30, 2025
Furniture, fixtures, equipment & leasehold improvements$4,771$3,960
Software323323
Capital improvements in progress36327
Gross property and equipment5,1304,610
Accumulated depreciation and amortization(2,557)(2,215)
Property and equipment, net$2,573$2,395

Depreciation and amortization expense of property and equipment was $227 thousand and $247 thousand for thethree months ended* March 31, 2026,and2025,* respectively. Depreciation and amortization expense of property and equipment was $684 thousand and $718 thousand for thenine months ended* March 31, 2026and2025,* respectively. Total depreciation and amortization expense includes finance lease right-of-use asset amortization of $95 thousand and $69 thousand for each of thenine months ended* March 2026,and2025.*

(6) Intangible Assets, net

As of* March 31, 2026*, and* June 30, 2025*, intangible assets, net consisted of the following, respectively:

(In thousands)March 31, 2026June 30, 2025
Intangible asset$50$50
Accumulated amortization—(2)
Intangible Assets, net$50$48

The intangible asset consists of a license from a national laboratory for technology used in gas chromatographic products.

(7) Warranty Reserve

Astrotech offers its customers warranties on the products that it sells. These warranties typically provide for repairs and maintenance of the products if problems arise during a specified period after original shipment. Concurrent with the sale of products, the Company records a provision for estimated warranty expenses with a corresponding increase in cost of goods sold. The Company periodically adjusts this provision based on historical experience and anticipated expenses. The Company charges actual expenses of repairs under warranty, including parts and labor, to this provision when incurred. The current obligation for warranty provision is included in accrued expenses and other liabilities in the condensed consolidated balance sheets. The warranty reserve balance was $195 thousand and $197 thousand as of* March 31, 2026*, and* June 30, 2025*, respectively.

(8) Stockholders’** Equity**

Preferred Stock

The Company has issued 280,898 shares of Series D convertible preferred stock (“Series D Preferred Shares”), all of which were issued and outstanding as of* March 31, 2026.Series D Preferred Shares are convertible to common stock on aone*-to-thirty basis, representing approximately 8.4 million shares of common stock upon conversion. Series D Preferred Shares arenot callable by the Company. The holder of the preferred stock is entitled to receive, and we shall pay, dividends on shares equal to and in the same form as dividends actually paid on shares of common stock when, and if, such dividends are paid on shares of common stock.No other dividends are paid on the preferred shares. Preferred shares haveno voting rights. Upon liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary, the preferred shares have preference over common stock. The holder of Series D Preferred Shares has the option to convert said shares to common stock at the holder’s discretion.

12

Common Stock

The Company has issued 1,769,269 shares of common stock and has outstanding shares of common stock of 1,758,953 as of* March 31, 2026*. Treasury shares of 10,316 are the difference between issued and outstanding shares.

We didnot issue common stock during thethree months ended* March 31, 2026*.

Rights Plan

On* December 21, 2022,the Company’s Board of Directors adopted a limited duration stockholder rights plan (the “Rights Plan”) expiring December 20, 2023and declared a dividend ofone preferred share purchase right for each outstanding share of common stock to stockholders of record on January 5, 2023to purchase from the Companyone one*-thousandth of a share of Series A Junior Participating Preferred Stock, par value $0.001 per share, of the Company for an exercise price of $58.00 once the rights become exercisable, subject to the terms of and adjustment as provided in the related rights agreement.

On* December 18, 2023,the Company entered into AmendmentNo.* 1 to Rights Agreement between the Company and Equiniti Trust Company, as Rights Agent (the "Amendment"), which extended the Final Expiration Date (as defined in the Rights Plan) to* December 20, 2024.On December 12, 2024,the Company entered into AmendmentNo.* 2 to the Rights Agreement between the Company and the Rights Agent, which extends the Final Expiration Date to* December 20, 2025,unless the Final Expiration Date is further extended by the Company or the rights subject to the Rights Plan are earlier redeemed or exchanged by the Company in accordance with the terms of the Rights Plan. On December 12, 2025,the Company entered into AmendmentNo.* 3 to the Rights Agreement with the Rights Agent, which extends the Final Expiration Date to* December 20, 2026,*unless the Final Expiration Date is further extended by the Company in accordance with the terms of the Rights Plan. All other terms and conditions of the Rights Plan remain unchanged.

Warrants

A summary of the common stock warrant activity for thenine months ended* March 31, 2026*, is presented below:

Number of Shares Underlying Warrants (In thousands)Weighted Average Exercise PriceAggregate Fair Market Value at Issuance (In thousands)Weighted Average Remaining Contractual Term (Years)
Outstanding June 30, 202577$69.04$3,5530.63
Warrants issued————
Warrants exercised————
Warrants expired(27)92.53$1,758—
Outstanding March 31, 20265056.25$1,7960.01

Shelf Registration Statement

On* January 28, 2026,the Company filed a Registration Statement on Form S-3 (RegistrationNo.* 333-293023) (the “Shelf Registration Statement”), declared effective on* January 30, 2026by the SEC, which includes a base prospectus that allows the Company to offer and sell, from time to time, inone* or more offerings, common stock, preferred stock, debt securities, warrants, rights or units up to an aggregate public offering price of $30 million. As described in the Shelf Registration Statement, pursuant to General InstructionI.B.6 of Form S-3, inno event will the Company sell securities registered on the Shelf Registration Statement, in a public primary offering with a value exceeding more thanone-third of the Company’s public float in any12-month period so long as the Company’s public float remains below $75 million (the “Baby Shelf Limitation”). As of the date of the Shelf Registration Statement and after giving effect to the Baby Shelf limitation and the public float of the Company’s common stock, the Company* may*offer and sell shares of its common stock having an aggregate offering price of up to approximately $1,974,354. The Shelf Registration Statement is intended to preserve the Company’s flexibility to raise capital from time to time, if and when needed.

(9) Net Loss per Share

Basic net loss per share is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed based on the weighted average number of common shares outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method and the if-converted method. Potentially dilutive common shares include outstanding stock options and share-based awards.

13

The following table reconciles the numerators and denominators used in the computations of both basic and diluted net loss per share:

Three Months Ended · Nine Months Ended
March 31,March 31,
(In thousands, except per share data)2026202520262025
Numerator:
Net loss$(3,768)$(3,633)$(11,161)$(10,920)
Denominator:
Denominator for basic and diluted net loss per share — weighted average common stock outstanding1,6771,6651,6761,663
Basic and diluted net loss per common share:
Net loss per common share$(2.25)$(2.18)$(6.66)$(6.57)

All unvested restricted stock awards and convertible Series D preferred shares for thenine months ended* March 31, 2026*, arenot included in diluted net loss per share, as the impact to net loss per share would be anti-dilutive. Options to purchase 234,426 shares of common stock at exercise prices ranging from $4.73 to $175.50 per share outstanding as of* March 31, 2026*, werenot included in diluted net loss per share, as the impact to net loss per share would be anti-dilutive.

(10) Revenue Recognition

Astrotech recognizes revenue employing the generally accepted revenue recognition methodologies described under the provisions of Accounting Standards Codification ("ASC") Topic606 “Revenue from Contracts with Customers” (“Topic606”). The methodology used is based on contract type and how products and services are provided. The guidelines of Topic606 establish afive-step process to govern the recognition and reporting of revenue from contracts with customers. Thefive steps are: (i) identify the contract with a customer, (ii) identify the performance obligations within the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations within the contract, and (v) recognize revenue when or as the performance obligations are satisfied.

An additional factor is reasonable assurance of collectability. This necessitates deferral of all or a portion of revenue recognition until assurance of collection. For thethree months ended* March 31, 2026,one major customer accounted for substantially all of the $99 thousand in revenue. For thethree* months ended* March 31, 2025,two customers accounted for substantially all of the $534 thousand in revenue. For thenine* months ended* March 31, 2026,four major customers accounted for substantially all of the $787 thousand of the Company's revenue. For thenine* months ended* March 31, 2025,*the Company recognized $829 thousand in revenue, primarily from three customers, which represented a significant portion of our total revenue for the period.

Revenue from product and services sales are recognized when control of the goods is transferred to the customer which occurs at a point in time typically upon shipment to the customer or completion of the service. This standard applies to all contracts with customers. Warranty obligations associated with the sale of our products are assurance-type warranties that are a guarantee of the product’s intended functionality and, therefore, donot represent a distinct performance obligation within the context of the contract. Warranty expense is included in cost of sales.

Contract Assets and Liabilities.

The Company enters into contracts to sell products and provide services, and it recognizes contract assets and liabilities that arise from these transactions. The Company recognizes revenue and corresponding accounts receivable according to Topic606 and, at times, recognizes revenue in advance of the time when contracts give us the right to invoice a customer. The Company* mayalso receive consideration, per the terms of a contract, from customers prior to transferring goods to the customer. The Company records customer deposits as deferred revenue. Additionally, the Company may*receive payments, most typically for service and warranty contracts, at the onset of the contract and before services have been performed. In such instances, the Company records a deferred revenue liability. The Company recognizes these contract liabilities as sales after all revenue recognition criteria are met.

Revenue under long-term government contracts is recorded under the percentage of completion method. Revenue, billable under cost-plus-fixed-fee contracts, is recorded as costs are incurred and includes estimated earned fees in the proportion that costs incurred to date bear to total estimated costs. Costs include direct labor, direct materials, subcontractor costs and manufacturing and administrative overhead allowable under the contract. General and administrative expenses allowable under the terms of contracts are allocated per contract, depending on its direct labor and material proportion to total direct labor and material of all contracts. As contracts can extend overone or more accounting periods, revisions in earnings estimated during the course of work are reflected during the accounting period in which the facts become known. The Company doesnot generally provide an allowance for returns from our government customers because our customer agreements donot provide for a right of return.

Practical Expedients.

In cases where the Company is responsible for shipping after the customer has obtained control of the goods, the Company has elected to treat the shipping activities as fulfillment activities rather than as a separate performance obligation. Additionally, the Company has elected to capitalize the cost to obtain a contract only if the period of amortization would be longer thanone year. The Company only considers whether a customer agreement has a financing component if the period between transfer of goods and services and customer payment is greater thanone year.

14

Product Sales.

The Company recognizes revenue from sales of products upon shipment or delivery when control of the product transfers to the customer, depending on the terms of each sale, and when collection is probable. In the circumstance where terms of a product sale include subjective customer acceptance criteria, revenue is deferred until the Company has achieved the acceptance criteria unless the customer acceptance criteria are perfunctory or inconsequential. The Company generally offers customers payment terms of60 days or less.

Freight.

The Company records shipping and handling fees that it charges to its customers as revenue and related costs as cost of revenue.

Multiple Performance Obligations.

Certain agreements with customers include the sale of equipment involving multiple elements in cases where obligations in a contract are distinct and thus require separation into multiple performance obligations, revenue recognition guidance requires that contract consideration be allocated to each distinct performance obligation based on its relative standalone selling price. The value allocated to each performance obligation is then recognized as revenue when the revenue recognition criteria for each distinct promise or bundle of promises has been met.

The standalone selling price for each performance obligation is an amount that depicts the amount of consideration to which the entity expects to be entitled in exchange for transferring the good or service. When there is onlyone performance obligation associated with a contract, the entire amount of consideration is attributed to that obligation. When a contract contains multiple performance obligations, the standalone selling price isfirst estimated using the observable price, which is generally a list price net of an applicable discount, or the price used to sell the good or service in similar circumstances. In circumstances when a selling price isnot directly observable, the Company will estimate the standalone selling price using information available to it including its market assessment and expected cost, plus margin.

The timetable for fulfillment of each of the distinct performance obligations can range from completion in a short amount of time and entirely within a single reporting period to completion over several reporting periods. The timing of revenue recognition for each performance obligation* may*be dependent upon several milestones, including physical delivery of equipment, completion of site acceptance test, and in the case of after-market consumables and service deliverables, the passage of time.

(11) Fair Value Measurement

ASC Topic820 “Fair Value Measurement” (“Topic820”) defines fair value, establishes a market-based framework or hierarchy for measuring fair value, and expands disclosures about fair value measurements. Topic820 is applicable whenever assets and liabilities are measured and included in the financial statements at fair value. The fair value hierarchy established in Topic820 prioritizes the inputs used in valuation techniques intothree levels as follows:

Level1 - Quoted prices in active markets for identical assets or liabilities.

Level2 - Inputs other than Level1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that arenot active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level3 - Unobservable inputs that are supported by little orno market activity and are significant to the fair value of the assets or liabilities.

15

The following tables present the carrying amounts, estimated fair values, and valuation input levels of certain financial instruments as of* March 31, 2026*, and* June 30, 2025*:

Carrying · Fair Value Measured Using · Fair
(In thousands)AmountLevel 1Level 2Level 3Value
Available-for-Sale Investments
Short-Term Investments
Mutual Funds - Corporate & Government Debt3,9033,903——3,903
ETFs - Corporate & Government Debt--——-
Total Available-for-Sale Investments$3,903$3,903$—$—$3,903
Carrying · Fair Value Measured Using · Fair
(In thousands)AmountLevel 1Level 2Level 3Value
Available-for-Sale Investments
Short-Term Investments
Mutual Funds - Corporate & Government Debt9,8799,879——9,879
ETFs - Corporate & Government Debt5,2295,229——5,229
Total Available-for-Sale Investments$15,108$15,108$—$—$15,108

The value of available-for-sale securities with Level1 inputs is based on pricing fromthird-party pricing vendors, who use quoted prices in active markets for identical assets. The fair value measurements used for time deposits are considered Level2 and use pricing fromthird-party pricing vendors who use quoted prices for identical or similar securities in both active and inactive markets.

The carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, short-term investments, accounts receivable, accounts payable, and accrued expenses and other liabilities at fair value or cost, which approximates fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest.

As of the unaudited condensed consolidated balance sheets date, certain investment securities are required to be recorded at fair value with the change in fair value during the period being recorded as an unrealized gain or loss.

(12) Business Risk and Credit Risk Concentration Involving Cash

For thethree months ended* March 31, 2026and2025,* one andtwo customers, respectively, accounted for substantially all of the Company's revenue. For thenine months ended* March 31, 2026,and2025,* four andthree customers, respectively, accounted for substantially all the of the Company's revenue.

The Company maintains funds in bank accounts that* mayexceed the limit insured by the Federal Deposit Insurance Corporation (the “FDIC”). The risk of loss attributable to these uninsured balances is mitigated by depositing funds in what the Company believes to be high credit quality financial institutions. The Company hasnot* experienced any losses in such accounts. The general insurance limit is*$250,000* per separately insured depositor. The combined balances of these bank accounts as of* March 31, 2026,were $2.2 million acrosstwo* financial institutions.

(13) Stock-Based Compensation

We have granted equity incentives to employees and directors in the form of stock options and restricted stock awards. The total stock-based compensation expense for all equity incentives was $245 thousand and $152 thousand for thethree months ended* March 31, 2026*, and* March 31, 2025*, respectively. The total stock-based compensation expense for all equity incentives was $740 thousand and $629 thousand for thenine months ended* March 31, 2026,and March 31, 2025,*respectively.

16

Stock Options

The Company’s stock option activity for thenine months ended* March 31, 2026*, is as follows:

SharesWeighted Average Exercise Price
Outstanding at June 30, 2025213,113$15.36
Granted78,2504.84
Exercised——
Canceled or expired(56,937)7.62
Outstanding at March 31, 2026234,426$11.10

The aggregate intrinsic value was $0 for all of options exercisable and for all unvested options at* March 31, 2026*, because the fair value of the Company’s common stock was less than the exercise prices of these options.

The table below details the Company’s stock options outstanding as of* March 31, 2026*:

Range of Exercise pricesNumber OutstandingOptions Outstanding Weighted-Average Remaining Contractual Life (Years)Weighted-Average Exercise PriceNumber ExercisableOptions Exercisable Weighted-Average Exercise Price
$4.73 - 9.6984,6009.16$5.5623,169$6.18
$10.10 - 11.2775,1307.4910.1250,49010.12
$11.51 - 19.272,7557.4514.3236,83218.95
$159 - 175.501,9411.11170.331,941170.33
$4.73 - 175.50234,4268.0311.10112,432$14.97

Compensation costs recognized related to stock option awards were $73 thousand and $126 thousand for each of thethree months ended* March 31, 2026*, and2025, respectively. Compensation costs recognized related to stock option awards were $464 thousand and $480 thousand for each of thenine months ended* March 31, 2026,and2025,* respectively. The remaining stock-based compensation expense of $514 thousand related to stock options will be recognized over a weighted-average period of 1.59 years.

Restricted Stock

The Company’s restricted stock activity for thenine months ended* March 31, 2026*, is as follows:

SharesWeighted Average Grant Date Fair Value
Outstanding at June 30, 202585,834$14.11
Granted
Vested
Canceled or expired(4,050)10.41
Outstanding at March 31, 202681,784$17.32

Stock compensation expenses related to restricted stock were $172 thousand and $26 thousand for thethree months ended* March 31, 2026*, and2025, respectively. Stock compensation expenses related to restricted stock were $246 thousand and $149 thousand for thenine months ended* March 31, 2026,and2025,* respectively. The remaining stock-based compensation expense of $419 thousand related to restricted stock awards granted will be recognized over a weighted-average period of 1.72 years.

17

(14) Income Taxes

The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are established, when necessary, to reduce deferred tax assets to amounts that are more likely thannot to be realized. As of* March 31, 2026,*the Company has a valuation allowance against all of its net deferred tax assets.

For thenine months ended* March 31, 2026and2025,* the Company incurred pre-tax losses in the amount of $11.2 million and $10.9 million, respectively. The total effective tax rate was approximately 0% for thenine months ended* March 31 2026and2025.*

For each of thenine months ended* March 31, 2026and2025,* the Company’s effective tax rate differed from the federal statutory rate of 21%, primarily due to the valuation allowance placed against its net deferred tax assets

FASB ASC740, “Income Taxes” addresses the accounting for uncertainty in income tax recognized in an entity’s financial statements and prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken or expected to be taken on a tax return. The Company currently has approximately $763 thousand of uncertain tax positions as of* March 31, 2026,all of which are accounted as contra-deferred tax assets. The Company doesnot* expect any significant changes to its uncertain tax positions in the coming12 months.

Loss carryovers are generally subject to modification by tax authorities untilthree years after they have been utilized; as such, the Company is subject to examination for the fiscal years ended2001 through present for federal purposes and fiscal years ended2006 through present for state purposes.

(15) Commitments and Contingencies

From time to time, the Company is subject to legal and administrative proceedings, settlements, investigations, claims and actions. The Company’s assessment of the likely outcome of litigation matters is based on its judgment of several of factors including experience with similar matters, history, precedents, relevant financial and other evidence and facts specific to the matter. Notwithstanding the uncertainty as to the outcome, based upon the information currently available, management doesnot believe any matters, individually or in aggregate, will have a material adverse effect on the Company’s financial position or results of operations.

The Company establishes reserves for the estimated losses on specific contingent liabilities, for regulatory and legal actions where the Company deems a loss to be probable and the amount of the loss can be reasonably estimated. In other instances, the Company isnot able to make a reasonable estimate of liability because of the uncertainties related to the outcome or the amount or range of potential loss.

(16) Subsequent Events

Management has determined there areno subsequent events to report through* May 14, 2026.*

(17)

Related Party

During thenine months ended* March 31, 2026,the Company has incurred consulting expenses of $211 thousand dollars for services provided by a consultant who is the son‑in‑law of the Company’s Chief Executive Officer. The services primarily related to software services. The engagement and compensation terms were reviewed and approved in accordance with the Company’s related party transaction policy. Management believes the terms of this arrangement are similar to those that would be obtained from an unaffiliatedthird* party.

18

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are forward-looking statements for purposes of federal and state securities laws. Forward-looking statements may include the words “may,” “will,” “plans,” “believes,” “estimates,” “expects,” “intends,” and other similar expressions. Such statements are subject to risks and uncertainties that could cause our actual results to differ materially from those projected in the statements. Such risks and uncertainties include, but are not limited to:

●The adverse expectations regarding the global economy, inflation, the potential for recession and geopolitical tensions and any resulting sanctions, or wars;
●The effect of economic and political conditions in the United States or other nations that could impact our ability to sell our products and services or gain customers;
●Product demand and market acceptance risks, including our ability to develop and sell products and services to be used by governmental or commercial customers;
●The impact of trade barriers imposed by the U.S. government, such as import/export duties and restrictions, tariffs and quotas, and potential corresponding actions by other countries in which we conduct our business;
●Technological difficulties and potential legal claims arising from any technological difficulties;
●The risks related to the availability of, and cost inflation in, supply chain inputs, including labor, raw materials, commodities, packaging, and transportation;
●Uncertainty in government funding and support for key programs, grant opportunities, or procurements;
●The impact of competition on our ability to win new contracts;
●Our ability to meet technological development milestones and overcome development challenges; and
●Our ability to successfully identify, complete and integrate acquisitions.

While we do not intend to directly harvest, manufacture, distribute or sell cannabis or cannabis products, we may be detrimentally affected by a change in enforcement by federal or state governments and we may be subject to additional risks in connection with the evolving regulatory area and associated uncertainties. Any such effects may give rise to risks and uncertainties that are currently unknown or amplify others identified herein.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.

Although we believe that the assumptions underlying our forward-looking statements are reasonable, any of the assumptions could be inaccurate; therefore, we cannot assure you that the forward-looking statements included in this Quarterly Report on Form 10-Q will prove to be accurate. Considering the significant uncertainties inherent in our forward-looking statements, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Some of these and other risks and uncertainties that could cause actual results to differ materially from such forward-looking statements are more fully described in our Annual Report on Form 10-K for the fiscal year ended June 30, 2025 (the "2025 Form 10-K"), elsewhere in this Quarterly Report on Form 10-Q , or those discussed in other documents we filed with the SEC. Except as may be required by applicable law, we undertake no obligation to publicly update or advise of any change in any forward-looking statement, whether as a result of new information, future events, or otherwise. In making these statements, we disclaim any obligation to address or update each factor in future filings with the Securities and Exchange Commission (“SEC”) or communications regarding our business or results, and we do not undertake to address how any of these factors may have caused changes to discussions or information contained in previous filings or communications. In addition, any of the matters discussed above may have affected our past results and may affect future results, so that our actual results may differ materially from those expressed in this Quarterly Report on Form 10-Q and in prior or subsequent communications.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.